Hospital
Ronald Reagan UCLA Medical Center
Ronald Reagan UCLA Medical Center was paid $1.27M by Medicaid between Jan 2018 and Apr 2022, across 115 billing codes. Its largest line is 99221, — 17% of everything it billed.
33Billing provider infoRONALD REAGAN UCLA MEDICAL CENTER
LOS ANGELES, CA 90095
LOS ANGELES, CA 90095
33aNPI1447574538assigned 03/18/2010
33bProvider typeGeneral Acute Care Hospital
28Total paid$1.27M
24GClaims86,987
24DCodes billed115
24AFirst – last monthJan 2018 – Apr 2022
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#264 of 410
Median peer was paid$6.90M
This provider vs. median0.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,655 | $279K | |
| 2019 | 18,217 | $308K | |
| 2020 | 17,153 | $284K | |
| 2021 | 23,967 | $336K | |
| 2022 | 4,995 | $62K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99221 | 17% | 6,502 | 5,171 | $216K | |
| 80053 | Comprehensive metabolic panel | 8.1% | 5,674 | 4,744 | $103K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 8.0% | 1,739 | 709 | $101K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 5.1% | 2,931 | 2,423 | $65K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 4.5% | 837 | 772 | $57K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3.9% | 1,461 | 672 | $50K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.8% | 5,789 | 4,771 | $48K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.5% | 1,862 | 1,757 | $32K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.5% | 873 | 823 | $32K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.5% | 858 | 811 | $31K |
| 93325 | 2.4% | 305 | 294 | $30K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.2% | 1,083 | 847 | $28K |
103 more codes
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.0% | 853 | $25K |
| 80061 | Lipid panel | 1.9% | 1,782 | $24K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.6% | 1,107 | $20K |
| 0450 | Emergency room services | 1.5% | 503 | $19K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.4% | 1,823 | $17K |
| 99000 | 1.3% | 8,428 | $17K | |
| 83735 | 1.2% | 2,135 | $15K | |
| 85027 | 1.1% | 2,776 | $14K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.0% | 86 | $13K |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 1.0% | 104 | $13K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 566 | $13K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 330 | $13K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 375 | $12K |
| 80197 | <1% | 1,015 | $11K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 604 | $10K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 938 | $10K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 818 | $9K |
| 81001 | <1% | 2,667 | $9K | |
| 93320 | <1% | 116 | $9K | |
| 0370 | <1% | 273 | $8K | |
| 84100 | <1% | 1,737 | $8K | |
| 85610 | <1% | 1,327 | $8K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 405 | $8K |
| 0710 | <1% | 196 | $8K | |
| 83880 | <1% | 393 | $8K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 75 | $7K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 401 | $7K |
| 86140 | <1% | 1,034 | $7K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 429 | $7K |
| J3490 | Unclassified drugs | <1% | 2,593 | $7K |
| 86850 | <1% | 795 | $7K | |
| 86900 | <1% | 888 | $6K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 172 | $6K |
| 80076 | <1% | 777 | $6K | |
| 87497 | <1% | 106 | $5K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 200 | $4K |
| 82728 | <1% | 315 | $4K | |
| 80051 | <1% | 1,256 | $4K | |
| 85652 | <1% | 1,119 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 295 | $4K |
| 86481 | <1% | 74 | $4K | |
| 82565 | <1% | 1,473 | $4K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 188 | $4K |
| 86901 | <1% | 900 | $4K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 179 | $4K |
| 87631 | <1% | 128 | $3K | |
| 82570 | <1% | 588 | $3K | |
| 84439 | <1% | 287 | $3K | |
| 82947 | <1% | 1,311 | $2K | |
| 83550 | <1% | 263 | $2K | |
| A4649 | Surgical supply; miscellaneous | <1% | 3,564 | $2K |
| 83540 | <1% | 299 | $2K | |
| Q3014 | Telehealth originating site facility fee | <1% | 94 | $2K |
| 86592 | <1% | 382 | $2K | |
| 83615 | <1% | 285 | $2K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 13 | $2K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 133 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 179 | $2K |
| 83655 | <1% | 358 | $2K | |
| 84703 | <1% | 367 | $1K | |
| 71045 | Radiologic examination, chest; single view | <1% | 272 | $1K |
| 86480 | <1% | 29 | $1K | |
| 0949 | <1% | 34 | $1K | |
| 84520 | <1% | 599 | $1K | |
| 84484 | <1% | 226 | $905.42 | |
| H1001 | Prenatal care, at-risk enhanced service; antepartum management | <1% | 13 | $902.20 |
| 84156 | <1% | 285 | $840.01 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 348 | $812.79 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 424 | $799.94 |
| 87088 | <1% | 107 | $781.46 | |
| 90686 | <1% | 35 | $699.23 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 110 | $625.20 |
| 92550 | <1% | 13 | $574.79 | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 12 | $570.52 |
| 0250 | <1% | 341 | $559.99 | |
| 83690 | <1% | 159 | $454.76 | |
| 83605 | <1% | 38 | $358.67 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 18 | $329.48 |
| 82550 | <1% | 47 | $276.57 | |
| 82607 | <1% | 12 | $250.28 | |
| 87205 | <1% | 44 | $241.69 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 209 | $241.30 |
| 86225 | <1% | 13 | $220.61 | |
| 87077 | <1% | 52 | $218.97 | |
| 86160 | <1% | 22 | $207.34 | |
| J2704 | Injection, propofol, 10 mg | <1% | 130 | $199.52 |
| 87070 | <1% | 26 | $191.52 | |
| 87186 | <1% | 19 | $181.39 | |
| 99401 | <1% | 13 | $144.72 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 80 | $135.54 |
| 87340 | <1% | 13 | $127.50 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 90 | $121.04 |
| 36415 | Collection of venous blood by venipuncture | <1% | 126 | $106.00 |
| 73610 | <1% | 15 | $96.64 | |
| 85730 | <1% | 12 | $74.20 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 38 | $64.89 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 15 | $45.58 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 12 | $23.39 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 17 | $14.12 |
| 82962 | <1% | 27 | $4.71 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 26 | $4.68 |
| 0258 | 0% | 59 | $0.00 | |
| 96376 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialORLOFF, TATIANA (ACUTE CARE NURSE PRACTITIONER)